ES2090233T3 - Conjugados de polimeros biologicamente estables y polinucleotidos para tratar el lupus eritematoso sistemico. - Google Patents

Conjugados de polimeros biologicamente estables y polinucleotidos para tratar el lupus eritematoso sistemico.

Info

Publication number
ES2090233T3
ES2090233T3 ES91300262T ES91300262T ES2090233T3 ES 2090233 T3 ES2090233 T3 ES 2090233T3 ES 91300262 T ES91300262 T ES 91300262T ES 91300262 T ES91300262 T ES 91300262T ES 2090233 T3 ES2090233 T3 ES 2090233T3
Authority
ES
Spain
Prior art keywords
eritematoso
polynucleotides
biologically stable
systemic lupus
polymer conjugates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91300262T
Other languages
English (en)
Inventor
Michael J Conrad
Stephen Coutts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
La Jolla Pharmaceutical Co
Original Assignee
La Jolla Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by La Jolla Pharmaceutical Co filed Critical La Jolla Pharmaceutical Co
Application granted granted Critical
Publication of ES2090233T3 publication Critical patent/ES2090233T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Saccharide Compounds (AREA)
  • Polyamides (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

CONJUGADOS QUIMICAMENTE DEFINIDOS DE POLIMEROS BIOLOGICAMENTE ESTABLES, TALES COMO LOS POLIMEROS DE ACIDO D-GLUTAMICO Y LISINA-D, Y LAS DUPLICACIONES DE POLINUCLEOTIDOS DE AL MENOS 20 PARES BASE QUE TIENEN UNA GRAN ACTIVIDAD DE ENLACE PARA LOS AUTOANTICUERPOS ANTI-DSADN DEL LUPUS DEL HOMBRE. LAS DUPLICACIONES SON PREFERENTEMENTE HOMOGENEAS EN LONGITUD Y ESTRUCTURA Y ESTAN UNIDAS AL POLIMERO POR MEDIO DE LA REACCION EN UN GRUPO FUNCIONAL AMINOREACTIVO LOCALIZADO EN, O CERCANO AL FINAL DE CADA DUPLICACION. ESTOS CONJUGADOS SON TOLEROGENOS PARA EL LUPUS ERITEMATOSO SISTEMICO DEL HOMBRE.
ES91300262T 1990-01-16 1991-01-15 Conjugados de polimeros biologicamente estables y polinucleotidos para tratar el lupus eritematoso sistemico. Expired - Lifetime ES2090233T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46613890A 1990-01-16 1990-01-16
US07/494,118 US5162515A (en) 1990-01-16 1990-03-13 Conjugates of biologically stable polymers and polynucleotides for treating systemic lupus erythematosus

Publications (1)

Publication Number Publication Date
ES2090233T3 true ES2090233T3 (es) 1996-10-16

Family

ID=27041547

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91300262T Expired - Lifetime ES2090233T3 (es) 1990-01-16 1991-01-15 Conjugados de polimeros biologicamente estables y polinucleotidos para tratar el lupus eritematoso sistemico.

Country Status (15)

Country Link
US (2) US5162515A (es)
EP (1) EP0438259B1 (es)
JP (2) JPH05505520A (es)
AT (1) ATE139448T1 (es)
AU (1) AU640730B2 (es)
CA (2) CA2173878C (es)
DE (1) DE69120303T2 (es)
DK (1) DK0438259T3 (es)
ES (1) ES2090233T3 (es)
FI (1) FI107514B (es)
GR (1) GR3021113T3 (es)
IE (1) IE910131A1 (es)
NO (1) NO303940B1 (es)
PT (1) PT96503B (es)
WO (1) WO1991010426A1 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5447722A (en) * 1983-12-12 1995-09-05 University Of Manitoba Method for the suppression of an immune response with antigen-MPEG conjugates in nonsensitized individuals
US5391785A (en) * 1990-01-16 1995-02-21 La Jolla Pharmaceutial Company Intermediates for providing functional groups on the 5' end of oligonucleotides
US5268454A (en) * 1991-02-08 1993-12-07 La Jolla Pharmaceutical Company Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier
US5552391A (en) * 1990-01-16 1996-09-03 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
US6465188B1 (en) * 1990-06-11 2002-10-15 Gilead Sciences, Inc. Nucleic acid ligand complexes
EP1808183A3 (en) * 1993-09-08 2009-07-01 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
KR100361933B1 (ko) * 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
US5599912A (en) * 1993-09-10 1997-02-04 Coretech, Inc. Compounds and methods for suppressing an immune response to sulfomethoxozale containing substances
US5573916A (en) * 1994-05-19 1996-11-12 Coretech, Inc. Immunogenic constructs comprising b-cell and t-cell epitopes on common carrier
US5681700A (en) * 1994-05-25 1997-10-28 Oklahoma Medical Research Foundation Assay for pathogenicity of anti-DNA antibodies
US6280944B1 (en) 1994-05-25 2001-08-28 Oklahoma Medical Research Foundation Assay for pathogenicity of anti-DNA antibodies
US8071737B2 (en) 1995-05-04 2011-12-06 Glead Sciences, Inc. Nucleic acid ligand complexes
ES2336857T3 (es) * 1995-05-04 2010-04-16 Gilead Sciences, Inc. Complejos de ligandos de acido nucleico.
US5874409A (en) * 1995-06-07 1999-02-23 La Jolla Pharmaceutical Company APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
US6410775B1 (en) * 1995-06-07 2002-06-25 La Jolla Pharmaceutical Company APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
US5856446A (en) * 1995-07-07 1999-01-05 Autoimmune Inc. Method of treating rheumatoid arthritis with low dose type II collagen
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
AU3665699A (en) 1998-04-27 1999-11-16 Biocrystal Limited Compositions and methods for tolerization in immune complex-mediated disease progression
EP0963758A3 (en) * 1998-05-07 2000-03-22 Universiteit Gent Synthetic polyaminoacid complexes for delivery of nucleic acids to target cells
US6858210B1 (en) 1998-06-09 2005-02-22 La Jolla Pharmaceutical Co. Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same
US20010010818A1 (en) * 1998-12-09 2001-08-02 Engle Steven B. Methods and formulations for reducing circulating antibodies
US6458953B1 (en) * 1998-12-09 2002-10-01 La Jolla Pharmaceutical Company Valency platform molecules comprising carbamate linkages
US6399578B1 (en) * 1998-12-09 2002-06-04 La Jolla Pharmaceutical Company Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using same
CA2376057A1 (en) * 1999-06-08 2000-12-14 La Jolla Pharmaceutical Company Valency platform molecules comprising aminooxy groups
CN1399562A (zh) 1999-11-28 2003-02-26 拉卓拉药物公司 基于抗体亲和力来治疗狼疮的方法及使用这种方法的筛选方法和组合物
US6911535B2 (en) * 2000-03-22 2005-06-28 Solvlink Biosciences Biomolecule/polymer conjugates
CA2414076A1 (en) 2000-06-08 2001-12-13 La Jolla Pharmaceutical Company Multivalent platform molecules comprising high molecular weight polyethylene oxide
CN1511041A (zh) * 2001-05-17 2004-07-07 ������ҩ�����޹�˾ 利用抑制cd21的药剂治疗抗体介导的病变的方法
KR100985457B1 (ko) 2001-06-21 2010-10-06 다이나박스 테크놀로지 코퍼레이션 키메라 면역조절 화합물 및 그것들의 사용 방법
US7785610B2 (en) * 2001-06-21 2010-08-31 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same—III
US20030114405A1 (en) * 2001-08-13 2003-06-19 Linnik Matthew D. Methods of treating systemic lupus erythematosus in individuals having significantly impaired renal function
US7105135B2 (en) * 2001-10-16 2006-09-12 Lockheed Martin Corporation System and method for large scale detection of hazardous materials in the mail or in other objects
US20050266427A1 (en) * 2002-01-15 2005-12-01 Schwartz David A Biomolecule/polymer conjugates
AU2003303524A1 (en) * 2002-12-27 2004-07-29 La Jolla Pharmaceutical Company Methods of improving health-related quality of life in individuals with systemic lupus erythematosus
WO2004089422A2 (en) * 2003-03-30 2004-10-21 La Jolla Pharmaceutical Co. Methods of treating and monitoring systemic lupus erythematosus in individuals
AU2004230927B9 (en) * 2003-04-13 2011-12-01 Enzon Pharmaceuticals, Inc. Polymeric oligonucleotide prodrugs
WO2012138694A2 (en) * 2011-04-07 2012-10-11 Emory University Compositions comprising saccharide binding moieties and methods for targeted therapy
US10864279B2 (en) * 2016-12-16 2020-12-15 Industrial Technology Research Institute Linker-drug and antibody-drug conjugate (ADC) employing the same
CN113150064B (zh) * 2021-04-14 2023-04-11 中山大学 一种抗菌抗虫肽的人工合成方法及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4191668A (en) * 1977-02-03 1980-03-04 Scripps Clinic And Research Foundation Induction of immunological tolerance
US4220565A (en) * 1979-01-18 1980-09-02 Scripps Clinic & Research Foundation Immunochemical conjugates: method and composition
US5126131A (en) * 1983-01-24 1992-06-30 The Johns Hopkins University Therapeutic suppression of specific immune responses by administration of antigen-competitive conjugates.
US4650675A (en) * 1983-08-18 1987-03-17 The Children's Medical Center Corporation Oligonucleotide conjugates
US4751181A (en) * 1984-12-31 1988-06-14 Duke University Methods and compositions useful in the diagnosis and treatment of autoimmune diseases
ATE134880T1 (de) * 1988-04-04 1996-03-15 Lawrence A Potempa Bindung von immunkomplexen durch modifizierte formen von c-reaktiven proteinen
CA2098281A1 (en) * 1990-12-17 1992-06-18 Howard M. Dintzis Suppression of immune responses of oligomeric forms of antigen of controlled chemistry

Also Published As

Publication number Publication date
JP2001354569A (ja) 2001-12-25
IE910131A1 (en) 1991-07-17
CA2034197A1 (en) 1991-07-17
DK0438259T3 (da) 1996-07-15
NO922781L (no) 1992-07-14
FI107514B (fi) 2001-08-31
AU640730B2 (en) 1993-09-02
PT96503B (pt) 1998-07-31
DE69120303D1 (de) 1996-07-25
CA2034197C (en) 2001-07-17
FI923241A0 (fi) 1992-07-15
AU6941891A (en) 1991-07-18
US5276013A (en) 1994-01-04
EP0438259B1 (en) 1996-06-19
FI923241L (fi) 1992-07-15
DE69120303T2 (de) 1996-11-28
GR3021113T3 (en) 1996-12-31
NO922781D0 (no) 1992-07-14
CA2173878C (en) 2000-04-04
WO1991010426A1 (en) 1991-07-25
CA2173878A1 (en) 1991-07-17
EP0438259A1 (en) 1991-07-24
NO303940B1 (no) 1998-09-28
JPH05505520A (ja) 1993-08-19
ATE139448T1 (de) 1996-07-15
PT96503A (pt) 1991-10-31
US5162515A (en) 1992-11-10

Similar Documents

Publication Publication Date Title
DK0851925T3 (da) Humane Væksthormonvarianter
ES2090131T3 (es) Solucion antineoplasica y procedimiento para el tratamiento de neoplasmas.
DE69120303D1 (de) Konjugate aus biologisch stabilen Polymeren und Polynukleotiden zur Behandlung von systematischem Lupus erythematosus
MX9301634A (es) Quinuclidinas peptidicas.
GT199700089A (es) Derivados 6.6 o 6.7 -biciclicos sustituidos que contienen pirido o pirimido.
ES2171768T3 (es) Inhibidores de la resorcion osea y antagonistas de receptores de vitronectina.
ES2118251T3 (es) Preparaciones de microparticulas a base de copolimeros biologicamente degradables.
ES2131190T3 (es) Composicion que contiene efectores de circulacion mejorada y procedimiento de utilizacion de la indicada composicion.
ES2160397T3 (es) Composicion filmogena densa.
ES2181775T3 (es) Nuevos complejos de acido nucleico y de polimero, su procedimiento de preparacion y su utilizacion para la transfeccion de celulas.
ES2178668T3 (es) Naftilamidas como agentes del sistema nervioso central.
ES2194918T3 (es) Compuestos de tiazol y tiadiazol como ligando receptor de dopamina d3.
GT199800205A (es) Compuestos de indol 2,3-sustituidos como agentes anti-inflamatorios y analgesicos.
ES2001003A4 (es) Metodo para preparar polimeros de sulfometil-poliacrilamidas.
ES2132401T3 (es) Tetrahidro-1h-benzazepinonas y hexahidroazepinonas como antagonistas selectivos del receptor colecistoquinina-b.
ES2167356T3 (es) Utilizacion de tioureilenos y tiabendazol en enfermedades autoinmunitarias e inflamatorias de la piel.
ATE230613T1 (de) Polymere platinverbindungen
NO885807L (no) Gelsammensetning.
ES2018747A6 (es) Monofilamento sintetico perfumado a base de homo- o co-poliamidas y procedimiento de fabricacion.
ES2116722T3 (es) Polimeros de condensacion y de adicion con agrupaciones de bistetrametilpiperidiniloxi n,n'-puenteadas.
ES2169427T3 (es) Elastomeros modificados quimicamente y mezclas de los mismos.
RU96105126A (ru) Ранозаживляющее средство "эмпаркол"
GT199700003A (es) Compuestos de quinolina y quinazolina utiles en terapia.
PT7989Y (pt) Caravana com autolocutorios para utilizacao como postos telefonicos publicos
PE30098A1 (es) Dihidropirimidinas y usos de las mismas

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 438259

Country of ref document: ES

FG2A Definitive protection

Ref document number: 438259

Country of ref document: ES